Morgan Stanley analyst Patrick Wood lowered the firm’s price target on TransMedics (TMDX) to $80 from $87 and keeps an Equal Weight rating on the shares. The firm sees the company having “disruptive technology,” but argues that fears on market share loss are “fair.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMDX:
- Amazon invests $4B more in Anthropic, Gap reports Q3 beat: Morning Buzz
- TransMedics downgraded to Hold from Buy at Needham
- TransMedics price target lowered to $110 from $180 at Piper Sandler
- TransMedics price target lowered to $104 from $109 at Canaccord
- TransMedics price target lowered to $120 from $175 at TD Cowen